Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
240 participants
INTERVENTIONAL
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
NCT02547441
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
NCT02576860
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
NCT02576847
A 21 Day Pharmacokinetics Study in Papulopustular Rosacea
NCT02028286
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01318733
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
omiganan mid dose
omiganan mid dose once daily application for 12 weeks
omiganan
omiganan high dose
omiganan high dose once daily application for 12 weeks
omiganan
Vehicle group
Vehicle once daily application for 12 weeks
placebo
omiganan low dose
omiganan low dose once daily application for 12 weeks
omiganan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
omiganan
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* clinically significant abnormal findings that would interfere with study objectives
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maruho Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Radiant Research Inc.
Birmingham, Alabama, United States
ATS Clinical Research
Santa Monica, California, United States
The Savin Center, PC
New Haven, Connecticut, United States
Skin Care Research, Inc
Boca Raton, Florida, United States
Dunedin Research Specialists
Dunedin, Florida, United States
North Florida Dermatology Associates
Jacksonville, Florida, United States
Dawes Fretzin Clinical Research Group
Indianapolis, Indiana, United States
Grekin Skin Institute
Warren, Michigan, United States
Rochester General Medical Group Center for Dermatology at Linden Oaks
Rochester, New York, United States
Derm Research Center of NY Inc.
Stoney Brook, New York, United States
Wake Resarch
Raleigh, North Carolina, United States
Oregon Dermatology and Research Center
Portland, Oregon, United States
TriCities Skin and Cancer
Johnson City, Tennessee, United States
Tennessee Clinical Research Center
Nashville, Tennessee, United States
Progressive Clinical Research, PA
San Antonio, Texas, United States
Dermatology Research Center
Salt Lake City, Utah, United States
Virginia Clinical Research Inc.
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLS001-CO-PR-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.